My research focuses on the determinants of clinical or biological characteristics involved in therapeutic failures (recurrences, hemorrhages, deaths) under anticoagulant treatment in the management of venous thromboembolic events associated with cancer. To address this issue, we are developing strategies that consider determinants of complications specific to inter-patient variability, inter-cancer variability, and inter-treatment variability in the care of cancer patients. I propose solutions based on 1/prediction risk models using epidemiological data, 2/pharmacokinetic and pharmacodynamic studies in specific at-risk populations for failure, and finally, 3/biological data that opens up translational research.

Teaching of  the 2nd cycle of medical studies

2023 PhD in Cellular and Molecular Biology and Integrated Biology

2020 Board of Vascular Medicine

2019 Board of Clinical Chemistry,

2019 MD

2017 Master II in Integrated Preclinical and Clinical Pharmacology

2016 Master I in Physiology, Pharmacology, and Toxicology

2008 Master I in Integrated Systems Biology and Physiology

Others noticeable diplomas:  Diploma in Thrombosis and Hemorrhage Biochemistry, Diploma from the Center for Teaching Statistics in Public Health

• Orcid